Therapeutic and Diagnostic Pipelines
Listed below are the current Oncology, Infectious Disease & Transplant, Autoimmune, Neurology & Fibrosis, Platform & Reagent, and Diagnostic projects currently in the works for QIMR Berghofer. For a printable pdf of the following please click the following button.
Therapeutic Pipeline
Oncology
Completed
Started
Target
Undisclosed
Modality
mAb
Indication
Undisclosed
Pre-Clinical
Discovery
Lead
Lead Optimisation
Pre Clinical
Clinical
Phase I
Phase II
Partner
Partner
Target
CMV
Modality
CTL Platform
Indication
Glioblastoma
Pre-Clinical
Discovery
Lead
Lead Optimisation
Pre Clinical
Clinical
Phase I
Phase II
Target
EBV
Modality
CTL Platform
Indication
Head & Neck
Pre-Clinical
Discovery
Lead
Lead Optimisation
Pre Clinical
Clinical
Phase I
Phase II
Partner
Partner
Target
Undisclosed
Modality
mAb
Indication
Undisclosed
Pre-Clinical
Discovery
Lead
Lead Optimisation
Pre Clinical
Clinical
Phase I
Phase II
Partner
Partner
Target
EBV
Modality
TCR-T cell
Indication
Head & Neck
Pre-Clinical
Discovery
Lead
Lead Optimisation
Pre Clinical
Clinical
Phase I
Phase II
Partner
Partner
Target
CYT-AT1: EphA3
Modality
CAR-T
Indication
Solid Tumours/Hematological Tumours
Pre-Clinical
Discovery
Lead
Lead Optimisation
Pre Clinical
Clinical
Phase I
Phase II
Partner
Partner
Target
PDL1
Modality
Bicyclic Peptide
Indication
Solid Tumours
Pre-Clinical
Discovery
Lead
Lead Optimisation
Pre Clinical
Clinical
Phase I
Phase II
Partner
Partner
Target
SETDB1
Modality
Bicyclic Peptide
Indication
Solid Tumours
Pre-Clinical
Discovery
Lead
Lead Optimisation
Pre Clinical
Clinical
Phase I
Phase II
Partner
Partner
Target
G9a
Modality
Small Molecule
Indication
Solid Tumours
Pre-Clinical
Discovery
Lead
Lead Optimisation
Pre Clinical
Clinical
Phase I
Phase II
Target
Galectin-9
Modality
mAb
Indication
Solid Tumours
Pre-Clinical
Discovery
Lead
Lead Optimisation
Pre Clinical
Clinical
Phase I
Phase II
Partner
Partner
Target
PDL2
Modality
Protein
Indication
Solid Tumours
Pre-Clinical
Discovery
Lead
Lead Optimisation
Pre Clinical
Clinical
Phase I
Phase II
Target
HPV
Modality
TCR-T cell
Indication
Head & Neck/Cervical
Pre-Clinical
Discovery
Lead
Lead Optimisation
Pre Clinical
Clinical
Phase I
Phase II
Target
CYT-AT2: CD-19
Modality
CAR-T
Indication
Hematological Tumours
Pre-Clinical
Discovery
Lead
Lead Optimisation
Pre Clinical
Clinical
Phase I
Phase II
Partner
Partner
Target
CD226
Modality
Armoured CAR-T
Indication
Solid Tumours
Pre-Clinical
Discovery
Lead
Lead Optimisation
Pre Clinical
Clinical
Phase I
Phase II
Infectious Disease & Transplant
Completed
Started
Target
CMV
Modality
CTL Platform
Indication
Solid Organ Transplants
Pre-Clinical
Discovery
Lead
Lead Optimisation
Pre Clinical
Clinical
Phase I
Phase II
Target
JCPyV
Modality
CTL Platform
Indication
Multifocal Leukoencephalopathy
Pre-Clinical
Discovery
Lead
Lead Optimisation
Pre Clinical
Clinical
Phase I
Phase II
Target
BKPyV
Modality
CTL Platform
Indication
Undisclosed
Pre-Clinical
Discovery
Lead
Lead Optimisation
Pre Clinical
Clinical
Phase I
Phase II
Target
CMV
Modality
Vaccine
Indication
CMV Infection
Pre-Clinical
Discovery
Lead
Lead Optimisation
Pre Clinical
Clinical
Phase I
Phase II
Partner
Partner
Target
ACE2
Modality
Bicyclic Peptide
Indication
COPD
Pre-Clinical
Discovery
Lead
Lead Optimisation
Pre Clinical
Clinical
Phase I
Phase II
Target
gp350
Modality
mAb
Indication
EBV Associated PTLD
Pre-Clinical
Discovery
Lead
Lead Optimisation
Pre Clinical
Clinical
Phase I
Phase II
Target
Dengue Virus
Modality
Subviral RNA
Indication
Dengue Fever
Pre-Clinical
Discovery
Lead
Lead Optimisation
Pre Clinical
Clinical
Phase I
Phase II
Autoimmune, Neurology & Fibrosis
Completed
Started
Target
EBV
Modality
CTL Platform
Indication
Multiple Sclerosis
Pre-Clinical
Discovery
Lead
Lead Optimisation
Pre Clinical
Clinical
Phase I
Phase II
Partner
Partner
Target
Undisclosed
Modality
Protein
Indication
Undisclosed
Pre-Clinical
Discovery
Lead
Lead Optimisation
Pre Clinical
Clinical
Phase I
Phase II
Partner
Partner
Target
Galectin-9
Modality
mAb
Indication
Autoimmune
Pre-Clinical
Discovery
Lead
Lead Optimisation
Pre Clinical
Clinical
Phase I
Phase II
Partner
Partner
Target
mir-25
Modality
miRNA
Indication
Liver Fibrosis
Pre-Clinical
Discovery
Lead
Lead Optimisation
Pre Clinical
Clinical
Phase I
Phase II
Target
Undisclosed
Modality
mAb
Indication
Undisclosed
Pre-Clinical
Discovery
Lead
Lead Optimisation
Pre Clinical
Clinical
Phase I
Phase II
Partner
Partner
Target
Undisclosed
Modality
Small Molecule
Indication
Heart Failure/Sepsis
Pre-Clinical
Discovery
Lead
Lead Optimisation
Pre Clinical
Clinical
Phase I
Phase II
Diagnostics
Completed
Started
Biomarker
N/A
Indication
Seizure
Application
Seizure detection
Platform
EEG
Discovery
Prototype
Analytical Validation
Clinical Study
Marketed
Partner
Partner
Biomarker
CMV
Indication
CMV Infection
Application
Undisclosed
Platform
Undisclosed
Discovery
Prototype
Analytical Validation
Clinical Study
Marketed
Partner
Partner
Biomarker
CMV
Indication
CMV Infection
Application
Undisclosed
Platform
Undisclosed
Discovery
Prototype
Analytical Validation
Clinical Study
Marketed
Partner
Partner
Biomarker
CMV
Indication
CMV Infection
Application
In Vitro Diagnostic
Platform
Flow Cytometry
Discovery
Prototype
Analytical Validation
Clinical Study
Marketed
Partner
Partner
Biomarker
Panel of 6 glycoproteins
Indication
Oesophageal Adenocarcinoma
Application
Cancer diagnostic
Platform
Proteomics
Discovery
Prototype
Analytical Validation
Clinical Study
Marketed
Partner
Partner
Biomarker
Undisclosed
Indication
Oncology
Application
Cancer prognostic
Platform
Undisclosed
Discovery
Prototype
Analytical Validation
Clinical Study
Marketed
Partner
Partner
Biomarker
PDL-1 post-translation modification
Indication
Oncology
Application
Patient selection for immunotherapy
Platform
Flow cytometry or digital imaging
Discovery
Prototype
Analytical Validation
Clinical Study
Marketed
Biomarker
Exosomes containing THBS1, NID1, PTX3 & VCAN
Indication
Oncology
Application
Early stage pan-cancer diagnostic
Platform
Exosome isolation & ELISA
Discovery
Prototype
Analytical Validation
Clinical Study
Marketed
Biomarker
Panel of 7 miRNA
Indication
Melanoma
Application
Cancer diagnostic & patient selection
Platform
Fluidigm PCR
Discovery
Prototype
Analytical Validation
Clinical Study
Marketed
Biomarker
Eomes
Indication
Oncology & infection
Application
T cell exhaustion
Platform
IFA multiplex
Discovery
Prototype
Analytical Validation
Clinical Study
Marketed
Platforms and Reagents
Completed
Started
Technology
Antibody reagent against chikungunya virus
Indication
Chikungunya infection
Application
Research & development
Discovery
Prototype
Validation
Marketed
Partner
Partner
Technology
Human cardiac organoid in vitro model
Indication
Cardiology
Application
Drug discovery
Discovery
Prototype
Validation
Marketed
Partner
Partner
Technology
CYT-101: CMV CAR-T Platform
Indication
Primary and recurrent GBM
Application
Virus specific T-cells to treat cancers
Discovery
Prototype
Validation
Marketed
Partner
Partner
Keep exploring
The future is here
View our available technologies
Cell manufacturing
Q-Gen is Australia's leading and most innovative cell manufacturer.
Why Partner With Us?
Together, we can translate innovative lab discoveries into successful commercial ventures, which make a significant impact on patient lives, drive medical innovations, and create a healthier future for people around the world.